神经发育疗法对脑瘫患儿促红细胞生成素水平影响的研究  

The effect of NDT on erythropoietin levels in cerebral palsy

作　　者：姚汉云[1] 文芳[2] 孙杨[1] 肖玲[2] 程自立[2] 万均成[2] 

机构地区：[1]武汉大学人民医院神经内科,硕士研究生430060 [2]武汉大学人民医院神经精神病研究所,430060

出　　处：《卒中与神经疾病》2005年第6期356-358,349,共4页Stroke and Nervous Diseases

摘　　要：目的观察神经发育疗法(neurodevelopmental treat ment,NDT)对脑瘫(cerebral palsy,CP)患儿血清促红细胞生成素(erythropoietin,EPO)水平的影响。方法用双抗体夹心ABC-ELISA法分别检测CP组和CP高危因素新生儿(新生儿病例组)血清EPO水平变化,并分别与其对照组比较。结果CP组NDT治疗后血清EPO高于对照组和NDT治疗前(P均<0.01),NDT治疗前血清EPO水平与CP对照组比较无统计学差异(P>0.05);新生儿病例组血清EPO水平明显高于新生儿病例对照组(P<0.01)。结论EPO可以作为评估神经发育疗法疗效的生物学指标。Objective To observe the effect of neurodevelopmental treatment （NDT） on erythropoietin （EPO） levels in cerebral palsy （CP） and to investigate the role of erythropoietin in the mechanisms of cerebral palsy. Methods Serum samples of 31 CP patients,37 neonates （n = 37） who suffered asphyxia and/or infection and 20 controls were obtained and kept at - 40℃ until the time of measurement. EPO levels were measured by the enzyme-linked immunosorbent assay double sandwich method （ABC-ELISA）. Results The EPO levels in serum of CP patients with NDT treatment were higher than those in the CP patients before they treated with NDT treatment and control group. There was no difference between CP group before they treated with NDT treatment and control group with regard to serum EPO levels. EPO level in serum of neonate group was higher than that in control group. Conclusions EPO as a kind of neurotrophic and neuroprotective cytokine plays an important role in the pathogenesis of cerebral palsy. EPO can be used as an independent biomarker that reflects curative effect of NDT.

关 键 词：脑瘫 神经发育疗法 促红细胞生成素 

分 类 号：R742[医药卫生—神经病学与精神病学]